Clinical Trial: A Study of Mirdametinib in Infants and Toddlers With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas

U.S., Oct. 1 -- ClinicalTrials.gov registry received information related to the study (NCT07850635) titled 'A Study of Mirdametinib in Infants and Toddlers With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas' on Sept. 24.

Brief Summary: The purpose of this study is to determine the safety, pharmacokinetic (PK), and tolerability of multiple treatment cycles of oral mirdametinib in infants and toddlers (0 to less than [<] 24 months of age) with measurable neurofibromatosis type 1 (NF1) associated plexiform neurofibromas (PNs) that is symptomatic or asymptomatic but in a high-risk location with a high risk of morbidity.

Study Start Date: Dec. 10

Study Type: INTERVENTIONAL

Condition: Neurofibromatosis Type 1-Associated Plexifo...